Next CBD Product With False Claims Gets FTC Investigation, Not A Warning Letter
Executive Summary
"Warning letter phase is over ... We will be opening investigations and we will target companies making disease claims for CBD products," says FTC attorney Rich Cleland. Agency also looking to hold retailers responsible for third-party vendors' false claims.
You may also be interested in...
COVID-19 Claim Warnings To US CBD Firms? Yes; References To Unlawful Use Of Hemp? No
Seven of nine firms targeted in US regulators’ recent warning letters about unlawful COVID-19 claims are offering supplements containing hemp ingredients. Former naturopathic physician sentenced to prison and probation for conviction on charges linked to offering bogus COVID-19 treatments.
CBD Products For Children Could Connect The Dots To FDA's Problem For Congress
In addition to FDA and FTC attention, pediatric claims by Rooted Apothecary could get attention of US lawmakers, who FDA is asking to authorize it to more directly enforce against adulterated supplements. Violative claims include “Increasing evidence suggests that CBD oil is a powerful option for pain and autism. It seems like an attractive and safe option for children.”
FTC Senses Cloud Around CBD Consumer Health Advertising, Warns More Firms
FTC warned firms selling CBD oils, creams, capsules and gummies with common advertising theme emphasizing ingredient "as a treatment or cure for serious diseases." Some ads specified conditions including Alzheimer’s, multiple sclerosis, epilepsy, heart disease and stroke, claims likely to get FDA's attention, too.